Cannabidiol significantly reduces drop seizure frequency in LGS


• The trial met its primary endpoint, demonstrating that CBD (20 mg/kg/day), as an add-on to standard of care, produced significantly greater reductions in drop seizures vs. placebo in patients with Lennox-Gastaut Syndrome (LGS).

• CBD resulted in significantly greater reductions in total seizure and non-drop seizure frequency vs. placebo.

• CBD patients/caregivers were significantly more likely than patients taking placebo to report an improvement in overall condition as measured on the Subject/Caregiver Global Impression of Change (S/CGIC) scale.

• CBD resulted in more adverse events than placebo, but it was generally well tolerated.